Study identifier:APTA-2217-08
ClinicalTrials.gov identifier:NCT00246935
EudraCT identifier:N/A
CTIS identifier:N/A
A long-term study of APTA-2217 in patients with chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD)
Phase 3
No
Roflumilast
All
150
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
TANABE SEIYAKU Co., LTD.
No locations available
Arms | Assigned Interventions |
---|